EFFICACY OF AMVATARI RAS IN GOUT

CLINICAL EVALUATION OF THE EFFECT OF AMVATARI RAS IN GOUT DISEASE

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/06/025901

Enrollment

Registered

2020-06-16

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M109- Gout, unspecified

Interventions

Intervention1: Amavatari Ras: 2 tab 2 times for 6 months Control Intervention1: NIL: NIL

Eligibility

Inclusion criteria

Inclusion criteria: Patients with serum uric acid must be more than or equal to 6.8 mg/dL. Patients matching 2015 ACR-EULAR Gout Classification Criteria.

Exclusion criteria

Exclusion criteria: Patients with prior tumors, secondary gout, or missing information regarding the age of onset. Patients having diabetes, cardiac problems, tuberculosis, etc.

Design outcomes

Primary

Measure	Time frame
Serum Uric AcidTimepoint: Serum Uric Acid at every month for 3 months	—

Secondary

Measure	Time frame
NILTimepoint: NA	—

Countries

India

Contacts

Public ContactProf R B Sati

Main Campus, Uttarakhand Ayurved University

drsatirb@gmail.com8077747461

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026